The ELATIVE trial outcomes were recently published in the prestigious New England Journal of Medicine on November 13. This trial was led by an international consortium in which Ana Corregidor, MD, served as the Principal Investigator. Congratulations, Dr. Corregidor and the entire EBGCR team!

The study’s findings indicate that treatment with elafibranor demonstrated remarkable enhancements in crucial biochemical markers of cholestasis compared to the placebo.

View the article ” Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis”  here.